Get the Stockscreener App
2.60
5.45%
-0.15
Evaxion Biotech A S Adr stock is traded at $2.60, with a volume of 407.42K.
It is down -5.45% in the last 24 hours and down -43.17% over the past month.
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
See More
Previous Close:
$2.75
Open:
$2.76
24h Volume:
407.42K
Relative Volume:
0.19
Market Cap:
$17.23M
Revenue:
-
Net Income/Loss:
$-11.46M
P/E Ratio:
-0.1857
EPS:
-14
Net Cash Flow:
$-24.56M
1W Performance:
+5.91%
1M Performance:
-43.17%
6M Performance:
-79.20%
1Y Performance:
-87.85%
1-Day Range:
$2.56
$2.83
1-Week Range:
$2.22
$4.05
52-Week Range:
$2.22
$23.70
Evaxion Biotech A S Adr Stock (EVAX) Company Profile
Name
Evaxion Biotech A S Adr
Sector
Industry
Phone
-
Address
-
Compare EVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVAX
Evaxion Biotech A S Adr
|
2.60 | 17.23M | 0 | -11.46M | -24.56M | -14.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.11 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.52 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.67 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.93 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.25 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Evaxion Biotech A S Adr Stock (EVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Feb-12-24 | Initiated | H.C. Wainwright | Buy |
Evaxion Biotech A S Adr Stock (EVAX) Latest News
Top investors say Evaxion Biotech A/S ADR (EVAX) ticks everything they need - SETE News
Evaxion Biotech A/S ADR [EVAX] Investment Guide: What You Need to Know - Knox Daily
Evaxion Biotech A/S ADR (EVAX) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Palantir Technologies Surges 16.5% in Pre-Market Trading After Strong Q4 Earnings Report - HPBL
Evaxion Biotech (EVAX) Stock Analysis: Price Decline, Analyst Ratings and Financial Ratios – market - HPBL
Evaxion Biotech A/S ADR (EVAX) Receives Upgrades Amid Sharp Decline – Is It Time for Investors to Reevaluate? - HPBL
Spyre Therapeutics Inc (SYRE) stock analysis: A comprehensive overview - US Post News
Argo Blockchain Plc ADR (ARBK)’s stock price in review: A technical analysis - US Post News
Evaxion Biotech A/S ADR (EVAX)’s stock decline to 2.40 per share - US Post News
Daily Market Movement: Onconetix Inc (ONCO) Sees a 11.91 Increase, Closing at 0.61 - The Dwinnex
In the Green: Evaxion Biotech A/S ADR (EVAX) Closes at 2.40, Up/Down -2.24 from Previous Day - The Dwinnex
Market Insights: Kairos Pharma Ltd (KAPA)’s Notable Gain of 6.29, Closing at 1.52 - The Dwinnex
Palantir Technologies at a Crossroads: Sky-High Valuation or Looming Market Correction? - HPBL
Hodges Capital Management Takes $16.5 Million Stake in Palantir Technologies (PLTR) – market - HPBL
Major Pharma Giant's VC Fund Doubles Down on Evaxion Biotech in $10.8M Strategic Round - StockTitan
Evaxion Biotech stock hits 52-week low at $2.38 amid market challenges - Investing.com
Evaxion announces pricing of $10.8 million public offering - GlobeNewswire Inc.
European Equities Traded in the US as American Depositary Receipts Tread Water in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Gains 2% for Week - MSN
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading - MSN
Evaxion Biotech stock hits 52-week low at $3.06 amid sharp decline By Investing.com - Investing.com South Africa
Evaxion Biotech stock hits 52-week low at $3.06 amid sharp decline - Investing.com
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Tuesday Trading - MSN
Evaxion Biotech stock hits 52-week low at $0.81 amid market challenges - Investing.com India
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Flat for Week - MSN
European Equities Traded in the US as American Depositary Receipts Higher in Thursday Trading - MSN
Evaxion Biotech Announces 1:5 ADS Ratio Change, Effective January 2025 - StockTitan
European Equities Traded in the US as American Depositary Rise in Monday Trading - MSN
European Equities Traded in the US as American Depositary Rise in Thursday Trading - MSN
European Equities Traded in US as American Depositary Receipts Tread Water Friday, Up 3% for Week - MSN
European Equities Traded in the US as American Depositary Edge Higher in Thursday Trading - MSN
Evaxion Biotech stock hits 52-week low at $0.84 amid market challenges - Investing.com
European Equities Traded in the US as American Depositary Receipts Decline in Monday Trading - MSN
European Equities Traded in the US as American Depositary Fall in Wednesday Trading - MSN
Evaxion Biotech stock hits 52-week low at $0.92 - Investing.com
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Down 1.5% for Week - MSN
European Equities Traded in the US as American Depositary Lower in Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Slightly Higher in Wednesday Trading - MSN
Evaxion achieves preclinical success with AI cancer vaccine - Investing.com
Evaxion Biotech stock hits 52-week low at $1.19 - Investing.com
Evaxion Biotech Unveils Ambitious 2025 Roadmap: AI-Powered Vaccines, $10M Deal Potential, Clinical Milestones - StockTitan
European Equities Traded in the US as American Depositary Receipts Nudge Higher Tuesday Trading - MSN
European Equities Traded in the US as American Depositary Edge Higher in Wednesday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Flat in Monday Trading - MSN
European Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading - MSN
Evaxion Biotech stock hits 52-week low at $1.31 By Investing.com - Investing.com South Africa
Evaxion Biotech stock hits 52-week low at $1.31 - Investing.com
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower - MSN
Evaxion Biotech A S Adr Stock (EVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):